• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lifeward Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    3/2/26 4:15:11 PM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email
    false12-310001607962L300-00000002 Cabot Rd., Hudson, MAFloor 6Yokneam Ilit+508.251.11544.959.0123Ordinary Shares, par value NIS 0.25NASDAQ00016079622026-02-242026-02-24


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): February 24, 2026
     
    Lifeward Ltd.

    (Exact Name of Registrant as Specified in its Charter)
      
    Israel
     
    001-36612
     
    Not Applicable
    (State or Other Jurisdiction of Incorporation)
     
    (Commission File Number)
     
    (IRS Employer Identification No.)

    2 Cabot Rd., Hudson, MA
     
    01749
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: +508.251.1154

    Not applicable
    (Former name or former address, if changed since last report)

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading Symbol
     
    Name of each exchange on which registered
    Ordinary Shares, no par value
     
    LFWD
     
    Nasdaq Capital Market

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     

    Item 3.03          Material Modification to Rights of Security Holders.

    To the extent required by Item 3.03, the disclosure set forth in Item 5.03 is incorporated herein by reference.

    Item 5.03          Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On February 24, 2026 (the “Effective Date”), Lifeward Ltd. (the “Company”) effected a 1-for-12 reverse share split (the “Reverse Split”) of all of the Company’s ordinary shares, no par value per share (the “Ordinary Shares”), and, in connection therewith, adopted its Eighth Amended and Restated Articles of Association (the “Articles”).
     
    As previously reported in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on January 6, 2026, the Company held its Extraordinary General Meeting of Shareholders (the “Meeting”) on January 6, 2026, at which the Company’s shareholders approved amendments to the Company’s Articles to effect (i) a reverse share split of the Company’s Ordinary Shares by a ratio within a range of 1-for-2 to 1-for-12, to be effective at the ratio and on a date to be determined by the Company’s Board of Directors (the “Board”), and (ii) an increase in the Company’s authorized share capital to up to 100,000,000 Ordinary Shares following implementation of the Reverse Split. On January 30, 2026, the Finance Committee of the Board (the “Finance Committee”) approved a reverse share split ratio of 1-for-12 and on February 16, 2026, the Finance Committee approved amendments to the Articles to reflect (i) the implementation of the Reverse Split effective February 24, 2026 and (ii) an increase in the Company’s authorized share capital to 100,000,000 Ordinary Shares following implementation of the Reverse Split.
     
    The Reverse Split will apply to the Company’s outstanding warrants, including pre-funded warrants, and stock options. The number of the Company’s Ordinary Shares into which these outstanding securities are convertible or exercisable will be adjusted proportionately as a result of the Reverse Split. The exercise prices of any outstanding warrants or stock options will also be proportionately adjusted in accordance with the terms of those securities and the Company’s equity incentive plans.
     
    The Company undertook the Reverse Split with the objective of meeting the minimum $1.00 per ordinary share bid price requirement for maintaining the listing of its Ordinary Shares on The Nasdaq Capital Market. As a result of the Reverse Split, the number of Ordinary Shares held by each shareholder of the Company automatically consolidated on a twelve (old) Ordinary Share for one (new) Ordinary Share basis. On the Effective Date, the Company’s 18,339,098 Ordinary Shares issued and outstanding were reduced to approximately 1,528,098 Ordinary Share issued and outstanding, and the total number of the Company’s authorized Ordinary Shares under its Articles was increased from 75,000,000 Ordinary Shares to 100,000,000 Ordinary Shares. No fractional shares were issued in connection with the Reverse Split and fractions were rounded down to the nearest whole share.
     
    The Company’s Ordinary Shares began trading on a split-adjusted basis on The Nasdaq Capital Market on February 24, 2026, and will continue to trade under its existing symbol “LFWD.” The new CUSIP number for the Ordinary Shares following the Reverse Split is M8216Q309.
     
    The summary of the amendments to the Articles contained herein does not purport to be complete and is qualified in its entirety by reference to the full text of the Articles, a copy of which will be filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Lifeward Ltd.
     
     
     
    Dated: March 2, 2026
    By:
    /s/ Almog Adar
     
    Name:
    Almog Adar
     
    Title:
    Chief Financial Officer
     

    Get the next $LFWD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    SEC Filings

    View All

    Lifeward Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - Lifeward Ltd. (0001607962) (Filer)

    3/2/26 4:15:11 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. filed SEC Form 8-K: Leadership Update

    8-K - Lifeward Ltd. (0001607962) (Filer)

    2/27/26 4:14:36 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events

    8-K - Lifeward Ltd. (0001607962) (Filer)

    2/25/26 4:15:47 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Lifeward with a new price target

    Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

    2/10/25 7:00:44 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP of Market Access & Strategy Lynch Jeannine was granted 50,000 units of Ordinary Shares, increasing direct ownership by 109% to 96,067 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    12/12/25 4:49:11 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    VP of Market Access & Strategy Lynch Jeannine sold $1,018 worth of Ordinary Shares (1,591 units at $0.64) (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    9/4/25 5:07:28 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Financial Officer Adar Almog

    4 - Lifeward Ltd. (0001607962) (Issuer)

    8/13/25 5:44:12 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    12/17/24 8:55:09 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/27/24 8:03:53 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/26/24 7:07:36 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton

    Clinic days offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 consecutive years, with the goal of accelerating personal exoskeleton adoption Streamlined pathway from evaluation to real-world use of ReWalk for people living with spinal cord injury (SCI) HUDSON, Mass. and CHICAGO, March 02, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced a joint effort with Shirley Ryan AbilityLab, a global leader in physical medicine and rehabilitation. This collaboration will establish dedicated clinic days launching in

    3/2/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors

    IP and technology acquisition is expected to be highly accretive and to advance Lifeward's position as a diversified biomedical innovation companyWill Expand Lifeward's portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfolio Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced it has entered i

    2/25/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Announces Reverse Share Split

    HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that effective with the open of the market on February 24, 2026, the Company will complete a 1-for-12 reverse split of its ordinary shares. On January 6, 2026, the Company's shareholders voted to authorize the Company's Board of Directors to determine whether to effect a reverse share split of the Company's ordinary shares and, if so, to set a ratio to be effective on a date to be determined by the Board. The

    2/20/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Financials

    Live finance-specific insights

    View All

    Lifeward Ltd. Reports Third Quarter 2025 Financial Results

    Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and nine months ended September 3

    11/14/25 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report Third Quarter Financial Results on November 14, 2025

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its third quarter 2025 financial results before the markets open on Friday, November 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561Inte

    11/10/25 7:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. Reports Second Quarter 2025 Financial Results

    Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments for Lifeward Achieve

    8/14/25 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Leadership Updates

    Live Leadership Updates

    View All

    Lifeward Appoints Bob Marshall as Chairman of the Board

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. "On behalf of the Board and entire Lifeward team, I congratulate Joe on his appointment as Chief Executive Officer of Care Enablement at Fresenius Medical Care, a global leader

    12/19/25 4:05:00 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

    Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administrati

    7/7/25 11:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Names Mark Grant as New CEO

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

    5/19/25 8:30:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care